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ABSTRACT
Objectives The Digital Ulcers Outcome (DUO) Registry 
was designed to describe the clinical and antibody 
characteristics, disease course and outcomes of patients 
with digital ulcers associated with systemic sclerosis 
(SSc).
Methods The DUO Registry is a European, prospective, 
multicentre, observational, registry of SSc patients with 
ongoing digital ulcer disease, irrespective of treatment 
regimen. Data collected included demographics, SSc 
duration, SSc subset, internal organ manifestations, 
autoantibodies, previous and ongoing interventions and 
complications related to digital ulcers.
Results Up to 19 November 2010 a total of 2439 
patients had enrolled into the registry. Most were 
classifi ed as either limited cutaneous SSc (lcSSc; 52.2%) 
or diffuse cutaneous SSc (dcSSc; 36.9%). Digital ulcers 
developed earlier in patients with dcSSc compared with 
lcSSc. Almost all patients (95.7%) tested positive for 
antinuclear antibodies, 45.2% for anti-scleroderma-70 
and 43.6% for anticentromere antibodies (ACA). The fi rst 
digital ulcer in the anti-scleroderma-70-positive patient 
cohort occurred approximately 5 years earlier than the 
ACA-positive patient group.
Conclusions This study provides data from a large 
cohort of SSc patients with a history of digital ulcers. 
The early occurrence and high frequency of digital ulcer 
complications are especially seen in patients with dcSSc 
and/or anti-scleroderma-70 antibodies.
Systemic sclerosis (SSc) is a multisystem autoim-
mune disease characterised by microvascular dam-
age and excessive ﬁ brosis of the skin and various 
internal organs. Limited cutaneous SSc (lcSSc) 
and diffuse cutaneous SSc (dcSSc) subsets are 
also associated with the presence of a number of 
autoantibodies, the expression of which can be 
useful in the diagnosis, prognosis and SSc disease 
management.1
The European Medicines Agency (EMA) 
requested the establishment of a prospective reg-
istry of patients with ongoing digital ulcers asso-
ciated with SSc as a licensing requirement for 
bosentan in this indication. The Digital Ulcers 
Outcome (DUO) Registry enrols patients with 
digital ulcer disease regardless of their treatment 
status; however, a large proportion are receiving 
bosentan. This study provides valuable insights 
into this patient group and here we describe the 
clinical and autoantibody characteristics of these 
patients at enrolment.
METHODS
The DUO Registry was initiated in April 2008 as 
an EMA postapproval commitment (after approval 
of a new indication for bosentan ‘to reduce the 
number of new digital ulcers in patients with sys-
temic sclerosis and ongoing digital ulcer disease’).2 
Participating centres received approval from rel-
evant national and local ethics committees, data 
protection and health authorities. In line with an 
observational study design, physicians were asked 
to enter all consenting consecutive patients with 
ongoing digital ulcers associated with SSc, irrespec-
tive of treatment regimen. Patients received stan-
dard medical care and follow-up as determined by 
their physician. Data deﬁ nitions were informed by 
literature3 and scientiﬁ c committee consensus. Data 
collection included demographics, SSc disease dura-
tion, underlying disease classiﬁ cation (lcSSc, dcSSc, 
overlap SSc/mixed connective tissue disease and 
other), internal organ manifestations, autoantibod-
ies, history of interventions/complications related 
to digital ulcers, ongoing complications related to 
digital ulcers, and ongoing medications and func-
tional assessment based on a disease-speciﬁ c ques-
tionnaire. The presence of antinuclear antibodies, 
anti-scleroderma-70 antibodies, anticentromere 
antibodies (ACA), anti-RNA polymerase 3, anti-U1 
ribonucleoprotein and anti-U3 ribonucleoprotein 
were recorded. All serology tests and other data 
collection parameters were collected if performed. 
Quality assurance comprised automatic online 
quality checks and annual source data veriﬁ cation 
on 10% of the patients.
Data analysis
Enrolment data for the antibody subsets were anal-
ysed cross-sectionally for differences by group. SAS 
statistical software was used for analysing the data. 
Descriptive statistics (mean, median, SD, 95% CI, 
minimum, maximum) are provided for numerical 
variables. Categorical variables are summarised by 
counts and percentages and 95% CI.
RESULTS
As of 19 November 2010, a total of 2439 patients 
had been enrolled into the DUO Registry from 271 
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table is published online only. 
To view this fi le please visit 
the journal online (http://ard.
bmj.com/content/71/5.toc).
1Centre for Rheumatology and 
Connective Tissue Diseases, 
Royal Free Hospital, London, UK
2Department of Dermatology, 
University of Cologne, Cologne, 
Germany
3Department of Internal 
Medicine, Paris Descartes 
University, Paris, France
4Actelion Pharmaceuticals Ltd, 
Allschwil, Switzerland
5Department of Medicine, 
University of Florence, Florence, 
Italy
Correspondence to 
Christopher P Denton, Centre for 
Rheumatology and Connective 
Tissue Diseases, Department 
of Infl ammation, Division of 
Medicine, UCL Medical School, 
Royal Free Campus, 
Rowland Hill Street, 
London NW3 2PF, UK; 
cdenton@medsch.ucl.ac.uk
*The complete list of DUO 
Registry investigators is 
provided as online supplement 
Appendix 1
Accepted 11 December 2011
Received 19 August 2011
Published Online First 
12 January 2012
CONCISE REPORT
Demographic, clinical and antibody characteristics of 
patients with digital ulcers in systemic sclerosis: data 
from the DUO Registry
Christopher P Denton,1 Thomas Krieg,2 Loic Guillevin,3 Barbara Schwierin,4 
Daniel Rosenberg,4 Mariabeth Silkey,4 Maurice Zultak,4 Marco Matucci-Cerinic,5 
on behalf of the DUO Registry investigators*
17_annrheumdis-2011-200631.indd   718 3/30/2012   7:01:06 PM
 o
n
 22 February 2019 by guest. Protected by copyright.
http://ard.bmj.com/
Ann R
heum
 D
is: first published as 10.1136/annrheum
dis-2011-200631 on 12 January 2012. Downloaded from
 
Clinical and epidemiological research
Ann Rheum Dis 2012;71:718–721. doi:10.1136/annrheumdis-2011-200631 719
participating centres in 18 European countries (Austria, Czech 
Republic, Denmark, Finland, France, Germany, Greece, Ireland, 
Italy, The Netherlands, Norway, Portugal, Slovakia, Slovenia, 
Spain, Sweden, Switzerland and UK).
Study cohort characteristics
The mean age of the patients enrolled was 54.6 years (SD 14.1) 
and the majority were women. Age at ﬁ rst Raynaud’s phenom-
enon was on average 39.8 years and age at ﬁ rst digital ulcer was 
46.7 years. At the time of enrolment, 60.0% (1426/2377) had 
at least one digital ulcer (data were missing for 62 patients). All 
patients who had no current digital ulcers at enrolment had a 
history of digital ulcer disease. Overall, 52.2% of the patients 
were classiﬁ ed as lcSSc, 36.9% as dcSSc, 6.8% as overlap SSc/
mixed connective tissue disease, and 4.1% had other diseases 
(eg, systemic lupus erythematosus, dermatomyositis, vasculitis 
or SSc not further speciﬁ ed) (data were missing for 44 patients).
At enrolment, gastrointestinal tract manifestations had 
occurred in more than half of the patients (55.7%). Also com-
mon were lung ﬁ brosis (41.3%), pulmonary arterial hyperten-
sion (PAH) (15.0%) and heart manifestations (10.7%). Almost 
half of all patients (47.4%) were receiving treatment with 
bosentan or another ERA (endothelin receptor antagonist), with 
a similar proportion receiving calcium antagonists and approxi-
mately one third receiving prostanoids (see supplementary table 
S1, available online only).
Antibody distribution
Almost all, 95.7%, (2085/2179) of patients tested were positive 
for antinuclear antibodies, 45.2% (854/1888) for anti-scleroder-
ma-70 antibodies, 43.6% (775/1778) for ACA, 9.9% (86/867) 
for anti-RNA polymerase 3, 9.7% (120/1243) for anti-U1 ribo-
nucleoprotein and 4.9% (39/799) for anti-U3 ribonucleoprotein. 
Few patients had a combination of antibodies. The combina-
tion with the highest occurrence was anti-scleroderma-70 plus 
ACA, 2.3% (56/2439), followed by anti-scleroderma-70 plus 
anti-U1 ribonucleoprotein, 1.8% (43/2439), anti-scleroderma-70 
plus anti-RNA polymerase 3, 1.5% (36/2439), ACA plus anti-U1 
ribonucleoprotein, 1.4% (34/2439), ACA plus anti-RNA poly-
merase 3, 1.4% (34/2439) and anti-U1 ribonucleoprotein plus 
anti-U3 ribonucleoprotein, 1.3% (31/2439).
SSc disease characteristics by antibody status
Patients positive for ACA were predominantly classiﬁ ed as 
lcSSc (82.9%; table 1). From the patients positive for anti-scle-
roderma-70 antibodies, a high proportion were classiﬁ ed as 
dcSSc (66.6%) and a lower proportion were classiﬁ ed as lcSSc 
(29.4%). Lung ﬁ brosis was most frequent in the anti-scleroder-
ma-70 subset (62.2%) compared with other antibody subsets 
(22.3–41.9%). Gastrointestinal manifestations showed a similar 
high proportion in all antibody subgroups, except for patients 
who were anti-U3 ribonucleoprotein positive. The frequencies 
of PAH and kidney manifestations were generally similar across 
the antibody subsets, although the proportion among patients 
with anti-U3 ribonucleoprotein was slightly higher; heart mani-
festations were highest in patients with anti-scleroderma-70 
and anti-U1 ribonucleoprotein and lowest in patients with ACA 
(table 2). The proportion of patients with previous digital ulcer 
complications and interventions was broadly similar in the anti-
scleroderma-70 subgroup and the ACA subgroup; the most 
marked exception was for surgical amputation, which occurred 
almost twice as frequently in patients with ACA (14.6%) 
compared with anti-scleroderma-70-positive patients (7.9%) 
(table 3).Ta
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Onset of disease manifestations by antibody status
In anti-scleroderma-70-positive patients, the ﬁ rst digital ulcer 
occurred at a mean age of 44.7 years (95% CI 43.6 to 45.7), 
whereas in ACA-positive patients, the ﬁ rst digital ulcer 
occurred approximately 6 years later, at 50.1 years (95% CI 
48.9 to 52.3).
Compared with ACA-positive patients, anti-scleroderma-70
-positive patients were younger at the onset of ﬁ rst Raynaud’s 
phenomenon symptoms (anti-scleroderma-70: 38.5 years (95% 
CI 37.5 to 39.6); ACA: 41.1 years (95% CI 39.9 to 42.3)) and had 
shorter time periods from the onset of Raynaud’s phenomenon 
to the ﬁ rst digital ulcer (anti-scleroderma-70: 6.0 years (95% CI 
5.4 to 6.6); ACA: 8.1 years (95% CI 7.3 to 9.0)) (table 1).
DISCUSSION
The ﬁ ndings of the DUO Registry regarding the burden of 
disease in SSc patients with digital ulcers conﬁ rm the ﬁ nd-
ings of other large cohort studies.4 5 Organ manifestations are 
common, with gastrointestinal manifestations being the most 
frequently reported, followed by lung ﬁ brosis, PAH and heart 
manifestations.
Complications associated with digital ulcers, such as infec-
tion requiring systemic antibiotics, gangrene and amputation 
occurred frequently in all major SSc subsets. Anti-scleroderma-
70-positive patients were younger at the onset of the ﬁ rst digi-
tal ulcer and had approximately double the rate of lung ﬁ brosis 
compared with ACA-positive patients, these data are in line 
with ﬁ ndings from the European League Against Rheumatism 
Scleroderma Trials and Research.4 Furthermore, heart mani-
festations were also more common in the anti-scleroderma-
70-positive group. Taken together, these ﬁ ndings conﬁ rm the 
association between anti-scleroderma-70 and more severe dis-
ease seen in other studies.1
The data show that anti-scleroderma-70-positive patients 
have fewer surgical amputations than ACA-positive patients 
but more autoamputation. As patients with this antibody have 
more SSc disease manifestations, the physician may be more 
reluctant to perform surgical interventions with the patient 
being more likely to be left to autoamputation; whereas ACA-
positive patients may have a phenotype that leads to a decision 
to amputate surgically.
The proportion of anti-U1 ribonucleoprotein in patients with 
SSc, at approximately 30% in both lcSSc and dcSSc, was much 
higher than the previously reported ﬁ gures.1 In contrast to other 
studies, the presence of anti-U1 ribonucleoprotein did not appear 
to have a greater association with PAH or with gastrointestinal 
manifestations than other autoantibodies.1
The proportion of patients reported here as anti-U3 ribonu-
cleoprotein positive was low (4.9%), a ﬁ nding similar to that 
reported in other studies.1 In addition, the complications associ-
ated with anti-U3 ribonucleoprotein positivity were similar as in 
previous studies.6–10
There are a number of limitations in this study. The DUO 
Registry is an observational study and not all data ﬁ elds were 
completed for every patient; for example, the number of digital 
ulcers at enrolment was missing for 62 patients and few patients 
were tested for anti-RNA polymerase 3 or for anti-U3 ribonu-
cleoprotein antibodies. Central testing was not performed and 
therefore potential variations between different analysis meth-
ods should be considered when interpreting the data.
In addition, at enrolment, differential recall bias for data 
recorded in the past may confound interpretation.
Almost half of all patients were being treated with bosentan. 
This is likely to be a reﬂ ection of the fact that the DUO Registry Ta
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was initiated following EMA approval of bosentan,2 and it is 
possible that patient entry into the registry was biased towards 
patients receiving bosentan. Therefore, there are limitations 
in the application of these data to the wider SSc population. 
Nevertheless, this study provides, and will continue to provide, 
valuable prospectively collected data from a large cohort of over 
2000 SSc patients. The strengths include the prospective nature 
of data collection and the strong framework of research gov-
ernance compared with that of previous studies. The multina-
tional and multicentre nature of this registry offers the potential 
for comparison of different patient populations and healthcare 
systems.
CONCLUSION
This report provides the ﬁ rst analysis of data from the large, mul-
tinational DUO Registry conﬁ rming the high clinical burden of 
digital ulcers in patients with SSc across antibody subsets, with 
early occurrence and high frequency in patients with dcSSc. The 
feasibility and utility of the DUO Registry is conﬁ rmed by the 
ﬁ ndings of this study.
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